Mundipharma
Laura García Montes is a financial professional with extensive experience in financial analysis and auditing. Currently serving as Controller Financiero at Mundipharma since September 2017, Laura has previously held positions such as Junior Project Controller at General Dynamics, where responsibilities included financial analysis and capital investment follow-up. Prior experience includes a role as Audit Assistant at EY, focusing on financial statement reviews under various regulatory frameworks, and an internship in the Financial Audit Department at EY, conducting financial statement analysis and auditing processes. Laura holds a Master's Degree in Financial Management and Controlling from EAE Business School and a Bachelor's degree in Economics from Universidad Autónoma de Madrid.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.